fbpx Skip to main content

MONDAY, Dec. 28, 2020 (HealthDay News) — Privileged White U.S. citizens have better health outcomes than average U.S. citizens for several health outcomes, but health outcomes are not always better than those in other developed countries, according to a study published online Dec. 28 in JAMA Internal Medicine.

Ezekiel J. Emanuel, M.D., Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues compared health outcomes of White U.S. citizens living in the 1 and 5 percent highest-income counties in the United States with residents in 12 other developed countries.

The researchers found that the infant mortality rate was 4.01 per 1,000 and the maternal mortality rate was 10.85 per 100,000 among White U.S. citizens in the 5 percent highest-income counties, which were both higher than the mean rates for any of the comparison countries. For White U.S. citizens in the 5 percent highest-income counties, the five-year survival rate was 67.2 percent for colon cancer, which was higher than that of the average U.S. citizen (64.9 percent), and higher, comparable, and lower than that of average citizens in six, four, and two comparison countries, respectively. For White children with acute lymphocytic leukemia in the 5 percent highest-income counties, the five-year survival rate was 92.6 percent, which was higher and comparable to one and 11 comparison countries, respectively.

“Being able to use social and financial capital in the United States to buy the best health care is not necessarily associated with the world’s best health outcomes,” the authors write.

Several authors disclosed financial ties to the biopharmaceutical and health insurance industries.

You May Also Like::  The Effects of a Low-Red and Processed Meat Diet on Health Parameters

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More